Drug intelligence / Profile preview

GTC-5000

Development stage: Unknown
Lead developer: Gismo Therapeutics
Modality: Small Molecules

Overview

GTC-5000 is a small molecule drug under development by Gismo Therapeutics. It acts as a modulator of α-synuclein, a protein implicated in the pathogenesis of Parkinson's disease and other neurodegenerative disorders. The drug is being investigated for its potential to modify α-synuclein activity, which may help address underlying mechanisms in nervous system diseases, particularly Parkinson's disease. As of June 2025, its highest development status is at the Discovery stage[1].

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on GTC-5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTC-5000.

Explore the full profile